Article Details

MorphoSys' Partner Incyte Announced Development and Commercialization Agreement ...

Retrieved on: 2021-08-17 06:33:45

Tags for this article:

Click the tags to see associated articles and topics

MorphoSys' Partner Incyte Announced Development and Commercialization Agreement .... View article details on hiswai:

Excerpt

About Tafasitamab Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive ...

Article found on: www.marketwatch.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up